药物治疗的精神分裂症患者的伐伦克林和 P50 听觉门控：一项初步研究。
Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.
机构信息
The Denver VAMC VISN19/MIRECC and UC Denver, School of Medicine, Department of Psychiatry, CO 80220, USA.
出版信息
Psychiatry Res. 2010 Jan 30;175(1-2):179-80. doi: 10.1016/j.psychres.2009.01.025. Epub 2009 Dec 2.
Abstract
Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating.
摘要
大多数精神分裂症患者存在听觉感觉门控缺陷，这种缺陷似乎是由α-7 烟碱型乙酰胆碱受体介导的。本研究旨在探讨 α-7 烟碱型乙酰胆碱受体激动剂瓦伦尼克林对 6 例精神分裂症患者 P50 听觉诱发电位的影响。但由于与 FDA 报告的副作用一致，该研究被取消。然而，在这一小部分受试者中，瓦伦尼克林并未一致增强 P50 听觉门控。
相似文献
1
Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.药物治疗的精神分裂症患者的伐伦克林和 P50 听觉门控：一项初步研究。
Psychiatry Res. 2010 Jan 30;175(1-2):179-80. doi: 10.1016/j.psychres.2009.01.025. Epub 2009 Dec 2.
2
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.中等剂量伐尼克兰治疗对患有精神分裂症或分裂情感性障碍的吸烟者及非吸烟者神经生物学和认知生物标志物的影响。
Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.
3
Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.抗精神病药物对首发未用药精神分裂症患者P50感觉门控的影响。
Schizophr Res. 2009 Mar;108(1-3):151-7. doi: 10.1016/j.schres.2008.11.016. Epub 2008 Dec 23.
4
The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.戒烟药物伐尼克兰可改善 DBA/2 小鼠的 P20-N40 抑制不足。
Pharmacol Biochem Behav. 2011 Nov;100(1):17-24. doi: 10.1016/j.pbb.2011.07.001. Epub 2011 Jul 7.
5
The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.伐尼克兰对烟碱或5-HT3A受体拮抗剂预处理后的感觉门控和探索行为的影响。
Behav Pharmacol. 2015 Feb;26(1-2):217-26. doi: 10.1097/FBP.0000000000000122.
6
Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.短期托烷司琼治疗与精神分裂症认知功能和 P50 听觉门控缺陷
Am J Psychiatry. 2012 Sep;169(9):974-81. doi: 10.1176/appi.ajp.2012.11081289.
7
Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.尼古丁感觉门控作用的基线依赖性：低、中、高 P50 抑制者的相似性和差异。
J Psychopharmacol. 2013 Sep;27(9):790-800. doi: 10.1177/0269881113490449. Epub 2013 Jun 6.
8
Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.海马体CA3区计算机模型中P50听觉诱发电位的多巴胺能调节：其与精神分裂症感觉门控的关系。
Biol Cybern. 2003 Apr;88(4):265-75. doi: 10.1007/s00422-002-0372-8.
9
Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.药物治疗的精神分裂症患者中N100中潜伏期听觉诱发电位的感觉门控缺陷。
Schizophr Res. 2009 Sep;113(2-3):339-46. doi: 10.1016/j.schres.2009.05.019. Epub 2009 Jun 12.
10
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.伐尼克兰用于精神分裂症患者戒烟：一项双盲随机试点研究。
Schizophr Res. 2011 Jun;129(1):94-5. doi: 10.1016/j.schres.2011.02.003. Epub 2011 Mar 4.
引用本文的文献
1
Cholinergic modulation of sensory perception and plasticity.胆碱能调制感觉感知和可塑性。
Neurosci Biobehav Rev. 2023 Sep;152:105323. doi: 10.1016/j.neubiorev.2023.105323. Epub 2023 Jul 17.
2
Selective 5HT3 antagonists and sensory processing: a systematic review.选择性 5HT3 拮抗剂与感觉处理：系统综述。
Neuropsychopharmacology. 2022 Mar;47(4):880-890. doi: 10.1038/s41386-021-01255-4. Epub 2022 Jan 11.
3
Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis.伐尼克兰用于精神分裂症患者戒烟的疗效与安全性：一项荟萃分析
Front Psychiatry. 2018 Sep 19;9:428. doi: 10.3389/fpsyt.2018.00428. eCollection 2018.
4
Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.啮齿动物海马听觉门控在精神分裂症研究中的转化应用：综述与评估
Transl Psychiatry. 2015 Jun 23;5(6):e587. doi: 10.1038/tp.2015.77.
5
Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.妊娠期补充胆碱可通过 Chrna7 基因敲除小鼠研究与α7 烟碱型乙酰胆碱受体相关联，从而长期改善感觉抑制作用。
Brain Res. 2014 Mar 13;1552:26-33. doi: 10.1016/j.brainres.2014.01.022. Epub 2014 Jan 23.
6
Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.化为乌有？基于烟碱型乙酰胆碱受体改善精神分裂症认知的治疗策略综述
Curr Pharm Des. 2014;20(31):5077-92. doi: 10.2174/1381612819666131216121019.
7
Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.美金刚和伐伦克林对有和无精神分裂症的非吸烟者认知表现的急性影响。
Psychopharmacology (Berl). 2014 Feb;231(4):765-75. doi: 10.1007/s00213-013-3286-3. Epub 2013 Oct 11.
8
A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.伐尼克兰在精神分裂症患者戒烟研究中的疗效与耐受性综述
J Addict Res Ther. 2011 Dec 20;S4(1). doi: 10.4172/2155-6105.S4-001.
9
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.用于治疗精神分裂症的毒蕈碱和烟碱型乙酰胆碱受体激动剂和变构调节剂。
Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28.
10
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.中等剂量伐尼克兰治疗对患有精神分裂症或分裂情感性障碍的吸烟者及非吸烟者神经生物学和认知生物标志物的影响。
Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.
本文引用的文献
1
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.伐尼克兰是α4β2的部分激动剂和α7神经元烟碱受体的完全激动剂。
Mol Pharmacol. 2006 Sep;70(3):801-5. doi: 10.1124/mol.106.025130. Epub 2006 Jun 9.
2
Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.伐尼克兰（一种选择性α4β2乙酰胆碱受体部分激动剂）在体内和体外的代谢与处置
Drug Metab Dispos. 2006 Jan;34(1):121-30. doi: 10.1124/dmd.105.006767. Epub 2005 Oct 12.
3
Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.昂丹司琼改善药物治疗的精神分裂症患者的p50听觉门控。
Am J Psychiatry. 2005 Feb;162(2):386-8. doi: 10.1176/appi.ajp.162.2.386.
4
Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.非典型抗精神病药物对精神分裂症患者P50听觉门控的不同影响。
Am J Psychiatry. 2004 Oct;161(10):1822-8. doi: 10.1176/ajp.161.10.1822.
5
Normalization of auditory physiology by cigarette smoking in schizophrenic patients.吸烟对精神分裂症患者听觉生理的正常化作用
Am J Psychiatry. 1993 Dec;150(12):1856-61. doi: 10.1176/ajp.150.12.1856.
6
Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval.
Biol Psychiatry. 1989 Mar 1;25(5):549-61. doi: 10.1016/0006-3223(89)90215-1.
7
Neurobiological studies of sensory gating in schizophrenia.精神分裂症感觉门控的神经生物学研究。
Schizophr Bull. 1987;13(4):669-78. doi: 10.1093/schbul/13.4.669.
8
Cholinergic gating of response to auditory stimuli in rat hippocampus.大鼠海马体中对听觉刺激反应的胆碱能门控
Brain Res. 1992 Jul 31;587(1):130-6. doi: 10.1016/0006-8993(92)91437-j.
9
Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics.尼古丁对精神分裂症患者亲属中听觉感觉门控缺陷的正常化作用。
Biol Psychiatry. 1992 Oct 1;32(7):607-16. doi: 10.1016/0006-3223(92)90073-9.
Zotero 插件